



KENNY C. GUINN
Governor

STATE OF NEVADA
DEPARTMENT OF HUMAN RESOURCES
DIVISION OF HEALTH CARE FINANCING AND POLICY
NEVADA MEDICAID

MICHAEL J. WILLDEN
Director

CHARLES DUARTE
Administrator

NOTICE OF OPEN PUBLIC MEETING

The Division of Health Care Financing and Policy ("DHCFP"), Pharmaceutical and Therapy Committee, will conduct a public meeting on **February 26, 2004** beginning at **1:00 p.m.** at the following location:

CARSON CITY
401 South Carson Street
Room 2135
Carson City

LAS VEGAS
555 E. Washington Avenue
Room 4406
Las Vegas

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Tiger Pope at: 775-684-3605 or toll free at: 1-800-992-0900, ext. 43605 in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Below is an agenda of all items scheduled to be considered. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.

Public comment may be limited to 5 minutes per person at the discretion of the Chairperson.

AGENDA

- I. Call to Order and Roll Call
- II. Welcome and Introductions
 - A. Chuck Duarte, Administrator, DHCFP
 - B. Committee Members
 - C. Agency Staff
 - D. First Health Services Staff
- III. Committee Background and Purpose – Chuck Duarte
- IV. Discussion of Open Meeting Law – Darrell Faircloth, DAG
- V. Discussion of Confidentiality and Conflict of Interest Statement
- VI. Discussion of Regulatory Authority – John Liveratti
- VII. *Approval of Bylaws
- VIII. Operational Overview of process to create the Preferred Drug List – Jeff Monaghan
- IX. *Approval of monthly schedule of the Drug Classes to be Reviewed
 - A. February 2004
 1. Angiotensin Converting Enzyme Inhibitors (ACEI's) and Combinations

1100 E. William Street, Suite 102, Carson City, Nevada 89701
(775) 684-3600

2. Angiotensin II Receptor Blocker (ARB's) and Combinations
 3. Gastrointestinal Agents
 - a. Proton Pump Inhibitors (PPI's)
 - b. Histamine-Two Receptor Antagonists (H2RA's)
 4. Bisphosphonates
- B. March 2004
1. Glaucoma Agents
 - a. Alpha2 Adrenergic Agent
 - b. Beta Blockers
 - c. Carbonic Anhydrase Inhibitors
 - d. Prostaglandin Agonists
 2. Agents in the Treatment of Hepatitis
 - a. Pegylated Interferons
 - b. Ribavirins
 3. Low Sedating Antihistamines and Combinations
 4. Beta Blockers: Oral Agents
- C. Determine schedule for remaining drug classes
- X. Public Comment on Drug Classes to be Reviewed in February
- XI. Presentation of February Class Reviews – First Health Services
- XII. *Committee Discussion of Drug Class Reviews for Angiotensin Converting Enzyme Inhibitors (ACEI's) and Combinations
- A. Determine Clinical/Therapeutic Equivalency of Agents for Angiotensin Converting Enzyme Inhibitors (ACEI's) and Combinations
 - B. Identify the need for exclusions/exceptions for certain patient groups
 - C. Determine Clinical Criteria for Prior Authorization for Angiotensin Converting Enzyme Inhibitors (ACEI's) and Combinations
- XIII. *Committee Discussion of Drug Class Reviews for Angiotensin II Receptor Blocker (ARB's) and Combinations
- A. Determine Clinical/Therapeutic Equivalency of Agents for Angiotensin II Receptor Blocker (ARB's) and Combinations
 - B. Identify the need for exclusions/exceptions for certain patient groups
 - C. Determine Clinical Criteria for Prior Authorization for Angiotensin II Receptor Blocker (ARB's) and Combinations
- XIV. *Committee Discussion of Drug Class Reviews for Gastrointestinal Agents, Proton Pump Inhibitors (PPI's)
- A. Determine Clinical/Therapeutic Equivalency of Agents for Proton Pump Inhibitors (PPI's)

- B. Identify the need for exclusions/exceptions for certain patient groups
- C. Determine Clinical Criteria for Prior Authorization for Proton Pump Inhibitors (PPI's)
- XV. *Committee Discussion of Drug Class Reviews for Gastrointestinal Agents, Histamine-Two Receptor Antagonists (H2RA's)
 - A. Determine Clinical/Therapeutic Equivalency of Agents for Histamine-Two Receptor Antagonists (H2RA's)
 - B. Identify the need for exclusions/exceptions for certain patient groups
 - C. Determine Clinical Criteria for Prior Authorization for Histamine –Two Receptor Antagonists (H2RA's)
- XVI. *Committee Discussion of Drug Class Reviews for Bisphosphonates
 - A. Determine Clinical/Therapeutic Equivalency of Agents for Bisphosphonates
 - B. Identify the need for exclusions/exceptions for certain patient groups
 - C. Determine Clinical Criteria for Prior Authorization for Bisphosphonates
- XVII. Recess
- XVIII. DHCFP's recommendation to the committee of drug(s) to be included on the Preferred Drug List based on committee's determination of clinical equivalency
- XIX. *Committee Action on DHCFP's recommendation to the committee of drug(s) to be included on the Preferred Drug List
- XX. *Approval of Future Meeting Schedule
- XXI. Public comment
- XXII. *Adjournment

*** Denotes items, including subparts, on which an action may be taken.**

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (dhcftp@state.nv.us).

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m. or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.